Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Jason M Warram"'
Autor:
Sindhu Nair, Hoa Q Trummell, Rajani Rajbhandari, Nanda K Thudi, Susan E Nozell, Jason M Warram, Christopher D Willey, Eddy S Yang, William J Placzek, James A Bonner, Markus Bredel
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0229077 (2020)
Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor. Monoclonal anti-EGFR antibody Cetuximab (CTX) provides significant clinical benefit in patie
Externí odkaz:
https://doaj.org/article/20ddfc5b974349a48705b8719e140d9b
Autor:
Christopher M Gentile, Anton V Borovjagin, Jillian R Richter, Aditi H Jani, Hongju Wu, Kurt R Zinn, Jason M Warram
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0215226 (2019)
BackgroundA major obstacle to using recombinant adenoviral vectors in gene therapy is the natural ability of human adenovirus to activate the classical and alternate complement pathways. These innate immune responses contribute to hepatic adenoviral
Externí odkaz:
https://doaj.org/article/f489c660c672461da2676c1bca0e467f
Autor:
Patrick N. Song, Shannon E. Lynch, Chloe T. DeMellier, Ameer Mansur, Carlos A. Gallegos, Brian D. Wright, Yolanda E. Hartman, Laura E. Minton, Suzanne E. Lapi, Jason M. Warram, Anna G. Sorace
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and hypoxia are associated with radioresistance. The goal of this study is to study the synergy of anti-HER2, trastuzumab, and anti-EGFR, cetuximab, an
Externí odkaz:
https://doaj.org/article/558a8968bead47b69cf936d5c973deaa
Supplementary Table 1 PDF file - 64K, Association of p-�-CaMKII IHC staining with osteosarcoma subtypes compared to normal bone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a507e947dace8288d0f78ca43aa839d
https://doi.org/10.1158/1541-7786.22510077
https://doi.org/10.1158/1541-7786.22510077
Supplementary Table 2 PDF file - 68K, Association of p-�-CaMKII IHC staining with osteosarcoma grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c2d16aaddbff1e70e47da5a1bef9d26
https://doi.org/10.1158/1541-7786.22510074
https://doi.org/10.1158/1541-7786.22510074
Autor:
Eben L. Rosenthal, Tong Zhou, Larissa Sweeny, Joseph A. Knowles, Jason M. Warram, Yolanda E. Hartman, Zhiyong Liu
Supplementary Figure 1 from Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da71be9f2c98013be1c1cdf2d5ce9ae
https://doi.org/10.1158/1541-7786.22519176
https://doi.org/10.1158/1541-7786.22519176
Osteosarcoma is among the most frequently occurring primary bone tumors, primarily affecting adolescents and young adults. Despite improvements in osteosarcoma treatment, more specific molecular targets are needed as potential therapeutic options. On
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d0a348d6ef025a3f3bb9215d5b9c181
https://doi.org/10.1158/1541-7786.c.6539499
https://doi.org/10.1158/1541-7786.c.6539499
Autor:
Eben L. Rosenthal, Tong Zhou, Larissa Sweeny, Joseph A. Knowles, Jason M. Warram, Yolanda E. Hartman, Zhiyong Liu
Supplementary Figure 2 from Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5850f7fa5d1287b5b41515cd88d4c455
https://doi.org/10.1158/1541-7786.22519173
https://doi.org/10.1158/1541-7786.22519173
Autor:
Eben L. Rosenthal, Sanjiv S. Gambhir, James P. Basilion, Michael F. Tweedle, John V. Frangioni, Christopher H. Contag, Jonathan Sorger, Michael Bouvet, Jamey P. Weichert, Brian W. Pogue, T. Joshua Pfefer, Betsy Ballard, Lori Henderson, Lalitha Shankar, Paula Jacobs, John Fengler, Kiranya E. Tipirneni, Jason M. Warram, Willemieke S. Tummers
Detailed overview of 510(k) cleared imaging devices by the FDA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c027f224445126231a348a1e82c5a4
https://doi.org/10.1158/0008-5472.22415555.v1
https://doi.org/10.1158/0008-5472.22415555.v1
Autor:
Kurt R. Zinn, Lisle M. Nabell, Lisa K. Clemons, Joshua S. Richman, William R. Carroll, Yolanda E. Hartman, Garima Agarwal, Anthony B. Morlandt, Cecelia E. Schmalbach, Theresa V. Strong, Margie Brandwein-Gensler, Melissa L. Korb, Thomas K. Chung, Esther de Boer, Jason M. Warram, Eben L. Rosenthal
Supplemental Figure S1 Pharmacokinetics of cetuximab-IRDye800. Supplemental Figure S2 Fluorescent imaging of positive margin using intraoperative instrument. Supplementary Figure S3 Opportunity for tissue saving procedures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6540f00fa8472b4716ec22e48f7130
https://doi.org/10.1158/1078-0432.22456533.v1
https://doi.org/10.1158/1078-0432.22456533.v1